Clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field & developing an oral obesity therapy Ticker: POLB
Poolbeg Pharma's TOPICAL trial will continue as planned following a positive interim safety review of POLB 001.
✅ No protocol changes required
✅ Recruitment ongoing across UK clinical sites
✅ Further enrolment, site activations and partnering discussions ahead
Read the full announcement & register for today's investor presentation:
londonstockexchange.com/news…#POLB#Biotech#AIM
Congratulations to Professor Luke O’Neill, Non-Executive Director & Scientific Advisory Board member of Poolbeg Pharma, on his appointment as Vice-President for Life Sciences at the European Research Council (ERC).
A fantastic recognition of Luke’s contribution to life sciences and his continued leadership within the European scientific community.
We are incredibly proud to have Luke as a member of the Poolbeg Pharma Board and wish him every success in this important new role.
A valuable week at #BIOEurope 2026 🌍
A highlight was CEO Jeremy Skillington joining a workshop on communicating complex science clearly to investors and pharma partners.
Highly relevant as Poolbeg Pharma advances POLB 001 and its partnering-led strategy.
#POLB
We’re looking forward to attending London Life Sciences Week 2026, connecting with biotech, pharmaceutical and life sciences leaders from across the industry.
Attending from Poolbeg will be:
🔵 Jeremy Skillington, CEO
🔵 Ian O'Connell, CFO
🔵 Cathal Friel, Executive Chair
Going to be there too? We’d be delighted to connect. Email IR@poolbegpharma.com to arrange a meeting with the team.
#LondonLifeSciencesWeek#Biotech#LifeSciences
CEO Jeremy Skillington, shares a quick overview of his workshop discussion, “Pitch, Present, Persuade: Become a Powerful #Corporate Communicator”, hosted by @OptimumComms on the opening day of #BIOEurope.
At Poolbeg, this is particularly relevant as we progress the #POLB 001 TOPICAL trial and continue #partnering discussions.
This #IrishScienceWeek, we celebrate the scientists and innovators advancing healthcare worldwide. 🔬
At Poolbeg Pharma, we're proud to be part of Ireland's thriving life sciences ecosystem, driving innovation to address unmet medical needs and improve patient outcomes.
#ScienceWeek#Biotech
🎤 #BIOEurope 2026! We’re looking forward to seeing our CEO, Jeremy Skillington, PhD, take part in the “Pitch, Present, Persuade: Become a Powerful Corporate Communicator” workshop at BIO-Europe on Monday, 9 November.
📍 Ecosystem Innovation Stage
📅 Monday, 9 November
⏰ 09:00–10:00
The session will bring together CEO, investor and BD perspectives to explore how biotech companies can communicate their science, strategy and commercial opportunity in a clear and compelling way.
Learn more:
informaconnect.com/bioeurope…#BIOEurope#Biotech#LifeSciences#BusinessDevelopment#PoolbegPharma
New to Poolbeg Pharma? 🎥 Our CEO Jeremy Skillington shares a quick overview of our lead asset POLB 001, its commercial opportunity and our partnering-led strategy.
🔹 POLB 001 – oral therapy to prevent Cytokine Release Syndrome associated with cancer immunotherapies
🔹 TOPICAL trial progressing, with recruitment ongoing and a positive review from the interim safety cohort
🔹 >$10bn market opportunity across multiple myeloma and diffuse large B-cell lymphoma
🔹 Strong partnering package supported by global IP, FDA Orphan Drug Designation, positive FDA pre-IND feedback and ongoing clinical development
🔹Active and ongoing partnering discussions with open data room
🔹 Funded into Q2 2028, providing a strong foundation as we advance our clinical and partnering objectives
Learn more about Poolbeg Pharma here:poolbegpharma.com/investors/#POLB#Investors#PoolbegPharma
A partner-ready biotech asset needs more than strong science.
At @_investorsummit , Chris Grimes-Crompton highlights the full equation for #POLB:
🔹Robust clinical evidence
🔹Clear value for payers
🔹A reimbursement case that protects asset value
Last night, our CEO Jeremy Skillington presented at the @ShardSB Investor Evening in London, sharing the Poolbeg Pharma story with attendees before an evening of networking.
A big thank you to Shard Capital for organising and to everyone who joined us, participated in the Q&A and spoke with the team afterwards.
📸 Check out some photos from the evening below.
You can also view the presentation deck used at the event on our website:
poolbegpharma.com/investors/…
🎙️ More Bitesize Biotech is coming soon… Have you tuned in to Episode 1?
bitesizebiotech.carrd.co/
In the first episode of Poolbeg Pharma’s #podcast series, Principal Scientist Liam Tremble is joined by Patient Advocate Bob Munro to discuss:
🔬 The role of the patient voice in #drugdevelopment
🧬 The real-world impact of medical innovation
🏥 The need to address #CRS#PoolbegPharma#BitesizeBiotech#Biotech#Healthcare
14 years after a myeloma diagnosis. 9–10 drugs over 11 years. Then a clinical trial led to Bob Munro’s first complete remission.
On #POLB’s Bitesize Biotech, Bob shares how new immunotherapies changed the course of his disease and opened up options when others had run out.
Tune into our podcast episode here: bitesizebiotech.carrd.co/